Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C
Background. The purpose of this study was to assess the efficacy and safety of low-dose peg-IFN α-2a plus ribavirin on the treatment of patients with chronic hepatitis C virus (HCV) infection. Patients and Methods. A total of 243 HCV patients treated with different doses of peg-IFN α-2a plus ribavir...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2012/302093 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549836799344640 |
|---|---|
| author | Zehui Yan Ke Fan Xiaohong Wang Qing Mao Guohong Deng Yuming Wang |
| author_facet | Zehui Yan Ke Fan Xiaohong Wang Qing Mao Guohong Deng Yuming Wang |
| author_sort | Zehui Yan |
| collection | DOAJ |
| description | Background. The purpose of this study was to assess the efficacy and safety of low-dose peg-IFN α-2a plus ribavirin on the treatment of patients with chronic hepatitis C virus (HCV) infection. Patients and Methods. A total of 243 HCV patients treated with different doses of peg-IFN α-2a plus ribavirin were stratified into three groups. End-of-treatment response (ETR) and sustained viral response (SVR) were evaluated for efficacy. Adverse events and laboratory abnormalities were conducted for safety. Results. ETR and SVR in group I were obtained in 83.9% and 68.9% of the patients, separately, which was similar to groups II (84.1% and 68.3%) and III (81.7% and 66.7%). The received peg-IFN α-2a dose was not the independent factor-related SVR in our population (OR, 1.31; 95% CI, 0.94–1.81; P=0.106). The frequency of no adverse events reported in group III (24.7%) was significantly higher than that in group I (11.5%) and group II (12.7%) (P=0.036). Conclusions. The peg-IFN α-2a 90 μg/week plus ribavirin is as effective as, and better tolerated than, peg-IFN α-2a standard dose with ribavirin in the treatment of chronic hepatitis C. This low-dose combination achieves high SVR rates and may be cost-saving. |
| format | Article |
| id | doaj-art-09c9b6d2ea06431b9829824795564ada |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-09c9b6d2ea06431b9829824795564ada2025-02-03T06:08:20ZengWileyGastroenterology Research and Practice1687-61211687-630X2012-01-01201210.1155/2012/302093302093Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis CZehui Yan0Ke Fan1Xiaohong Wang2Qing Mao3Guohong Deng4Yuming Wang5Institute of Infectious Diseases, Southwest Hospital, The Third Military Medical University, Chongqing 400038, ChinaInstitute of Infectious Diseases, Southwest Hospital, The Third Military Medical University, Chongqing 400038, ChinaInstitute of Infectious Diseases, Southwest Hospital, The Third Military Medical University, Chongqing 400038, ChinaInstitute of Infectious Diseases, Southwest Hospital, The Third Military Medical University, Chongqing 400038, ChinaInstitute of Infectious Diseases, Southwest Hospital, The Third Military Medical University, Chongqing 400038, ChinaInstitute of Infectious Diseases, Southwest Hospital, The Third Military Medical University, Chongqing 400038, ChinaBackground. The purpose of this study was to assess the efficacy and safety of low-dose peg-IFN α-2a plus ribavirin on the treatment of patients with chronic hepatitis C virus (HCV) infection. Patients and Methods. A total of 243 HCV patients treated with different doses of peg-IFN α-2a plus ribavirin were stratified into three groups. End-of-treatment response (ETR) and sustained viral response (SVR) were evaluated for efficacy. Adverse events and laboratory abnormalities were conducted for safety. Results. ETR and SVR in group I were obtained in 83.9% and 68.9% of the patients, separately, which was similar to groups II (84.1% and 68.3%) and III (81.7% and 66.7%). The received peg-IFN α-2a dose was not the independent factor-related SVR in our population (OR, 1.31; 95% CI, 0.94–1.81; P=0.106). The frequency of no adverse events reported in group III (24.7%) was significantly higher than that in group I (11.5%) and group II (12.7%) (P=0.036). Conclusions. The peg-IFN α-2a 90 μg/week plus ribavirin is as effective as, and better tolerated than, peg-IFN α-2a standard dose with ribavirin in the treatment of chronic hepatitis C. This low-dose combination achieves high SVR rates and may be cost-saving.http://dx.doi.org/10.1155/2012/302093 |
| spellingShingle | Zehui Yan Ke Fan Xiaohong Wang Qing Mao Guohong Deng Yuming Wang Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C Gastroenterology Research and Practice |
| title | Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C |
| title_full | Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C |
| title_fullStr | Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C |
| title_full_unstemmed | Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C |
| title_short | Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C |
| title_sort | efficacy and safety of low dose peginterferon alpha 2a plus ribavirin on chronic hepatitis c |
| url | http://dx.doi.org/10.1155/2012/302093 |
| work_keys_str_mv | AT zehuiyan efficacyandsafetyoflowdosepeginterferonalpha2aplusribavirinonchronichepatitisc AT kefan efficacyandsafetyoflowdosepeginterferonalpha2aplusribavirinonchronichepatitisc AT xiaohongwang efficacyandsafetyoflowdosepeginterferonalpha2aplusribavirinonchronichepatitisc AT qingmao efficacyandsafetyoflowdosepeginterferonalpha2aplusribavirinonchronichepatitisc AT guohongdeng efficacyandsafetyoflowdosepeginterferonalpha2aplusribavirinonchronichepatitisc AT yumingwang efficacyandsafetyoflowdosepeginterferonalpha2aplusribavirinonchronichepatitisc |